MARKET

SYRE

SYRE

Spyre Therapeutics
NASDAQ
29.68
+1.55
+5.51%
After Hours: 29.68 0 0.00% 16:01 07/12 EDT
OPEN
28.67
PREV CLOSE
28.13
HIGH
29.77
LOW
27.43
VOLUME
908.12K
TURNOVER
0
52 WEEK HIGH
47.97
52 WEEK LOW
8.43
MARKET CAP
1.51B
P/E (TTM)
-0.4160
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at SYRE last week (0701-0705)?
Weekly Report · 6d ago
Weekly Report: what happened at SYRE last week (0624-0628)?
Weekly Report · 07/01 10:59
Weekly Report: what happened at SYRE last week (0617-0621)?
Weekly Report · 06/24 11:05
LifeSci Capital Sticks to Their Buy Rating for Spyre Therapeutics (SYRE)
TipRanks · 06/18 21:05
Spyre Therapeutics Has Initiated Dosing Of Healthy Volunteers In Its First Clinical Trial Of SPY001 For Inflammatory Bowel Disease, Interim Subcutaneous Pharmacokinetic And Safety Data Anticipated By End Of 2024
Preclinical data for SPY001 shows potential for improved dosing over standard of care. All three next-generation antibodies targeting TL1A, IL-23 are on track to be in the clinic within 12 months. SPY002 is expected to begin first-in-human studies in the second half of 2024.
Benzinga · 06/18 11:33
SPYRE TO PRESENT INTERIM SPY001 DATA BY YEAR-END 2024
Reuters · 06/18 11:30
SPYRE THERAPEUTICS ANNOUNCES FIRST PARTICIPANTS DOSED IN PHASE 1 TRIAL OF SPY001, ITS NOVEL HALF-LIFE EXTENDED ANTI-Α4Β7 ANTIBODY, FOR THE TREATMENT OF INFLAMMATORY BOWEL DISEASE
Reuters · 06/18 11:30
SPYRE THERAPEUTICS: SPY002 REMAINS ON TRACK TO BEGIN FIRST-IN-HUMAN STUDIES IN H2 OF 2024
Reuters · 06/18 11:30
More
About SYRE
Spyre Therapeutics, Inc. is a biotechnology company. The Company is engaged in creating inflammatory bowel disease (IBD) products by combining antibody engineering, rational therapeutic combinations and precision medicine approaches. Its pipeline includes investigational extended half-life antibodies targeting a4B7, TL1A, and IL-23. Its pipeline programs include SPY003, SPY004, SPY130, and SPY230. It has nominated development candidates for SPY001 and SPY002. Its advanced product candidate, SPY001, is a fully human monoclonal immunoglobulin G1 antibody designed to bind selectively to the a4B7 integrin being developed for the treatment of IBD. Its co-lead program, SPY002, has nominated two fully human mAb candidates designed to bind to tumor necrosis factor-like ligand 1A (TL1A), both of which are in preclinical development for the treatment of IBD. SPY003 is a discovery-stage program focused on designing antibodies to bind to Interleukin 23 (IL-23).

Webull offers Spyre Therapeutics Inc stock information, including NASDAQ: SYRE real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SYRE stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading SYRE stock methods without spending real money on the virtual paper trading platform.